Smoking is the leading cause of preventable death in the United States. Efforts have been made to develop effective, integrated smoking-cessation treatments for individuals with greater difficulty quitting, including individuals with elevated anxiety sensitivity (AS). Despite initial evidence for the efficacy of these treatments, little is understood about pretreatment predictors of early treatment milestones, including treatment initiation and response. Positive affectivity (PA) and negative affectivity (NA) are unique mood traits that may be related to early treatment milestones. Indeed, PA and NA are related to smoking and mood outcomes generally. Yet, it is presently unknown if pretreatment PA or NA predict early treatment milestones within the context of an integrated smoking-cessation treatment. The current study sought to evaluate the independent effect of PA and NA on early treatment milestones within the context of an integrated smoking-AS treatment protocol. Smoking and AS outcomes were evaluated independently. Participants included 288 (50% female; M age ¼ 38.66, SD ¼ 13.67) treatment-seeking adult daily cigarette users. Results indicated that higher pretreatment NA was associated with an increased likelihood of early dropout versus responding to treatment across both outcomes (smoking: odds ratio [OR] 0.93, 95% confidence interval [CI] 0.88-0.99; AS: OR 0.92, 95% CI 0.88-0.98). Pretreatment PA did not significantly differentiate any of the groups. Overall, the present study serves as an initial investigation of the role of pretreatment NA in identifying those at greatest risk for dropping out of treatment (cf. responding to treatment).
C igarette smoking is a leading cause of preventable death and disease in the United States (CDCP, 2015) . Select subgroups of the general population are at greater risk for being smokers, and therefore, experience higher rates of smoking-related death and illness (Lasser et al., 2000) . One such subgroup is individuals with elevated anxiety sensitivity (AS). AS is commonly conceptualized as ''the fear of fear'' (Reiss and McNally, 1985) and is widely recognized as a common transdiagnostic, individual difference factor related to the development of psychopathology and the maintenance/ relapse of smoking (Zvolensky et al., 2006; Zvolensky et al., 2009; Langdon et al., 2016) .
The unique challenges individuals with elevated AS face when attempting to quit has led researchers to develop specialty care treatments to assist with this vulnerable and large subgroup of cigarette users (Zvolensky et al., 2003; Zvolensky et al., 2014; Smits et al., 2016; Zvolensky et al., 2018) . These novel treatments integrate traditional smoking-cessation treatment with AS reduction methods, typically consisting of psychoeducation, cognitive-behavioral restructuring strategies, and interoceptive exposure exercises (Zvolensky et al., 2018) . Substantial work has demonstrated the short and long-term efficacy of these treatments to increase abstinence and reduce AS symptoms (Zvolensky et al., 2008; Zvolensky et al., 2009; Zvolensky et al., 2014) . Nevertheless, once deemed eligible, not all persons participate in these programs or respond to these treatments, and little is understood about risk factors related to these ''early treatment milestones.'' From a phase-based perspective (Hughes, 1996; Hughes, 2008; Baker et al., 2011) , it is clinically necessary to elucidate pretreatment predictors of early treatment milestones, including pretreatment dropout (ie, dropping out of treatment prior to attending a single treatment session; Vendetti et al., 2002) and nonresponsiveness (ie, completing treatment, but not demonstrating significant improvement in outcomes at the end of treatment; Garey et al., 2017) . Indeed, understanding pretreatment factors that may help identify those at greatest risk for pretreatment dropout and treatment nonresponse has important clinical implications, including the potential to inform more personalized care and current recommendations for triaging smoking with elevated negative affective states (Knopp et al., 2013 ). Yet, this work has been overlooked when evaluating the efficacy of integrated AS smoking trials.
Available data implicate affective processes of smoking as important risk factors for poorer, early treatment milestones (Wynd, 2006; Garey et al., 2017) . Broadening this research, more general affective characteristics, such as positive affectivity (PA) and negative affectivity (NA), may be related to early smoking milestones. PA is characterized as the extent to which an individual feels calm, enthusiastic, active, and alert, whereas NA reflects states of distress and dissatisfying engagement in one's environment (Watson et al., 1988) . Increased PA is associated with greater persistence and retention in smoking-cessation treatment (Bränström et al., 2010b) . Conversely, increased NA has been identified as a risk factor for poorer cessation outcomes, including coping-oriented smoking (Carmody et al., 2007) . Evidence also suggests lower PA and higher NA are independently associated with smoking urge and relapse (Leventhal et al., 2013a; Piper et al., 2013) . Importantly, in models testing the concurrent role of PA and NA on smoking urge, only NA significantly relates to smoking urge (Leventhal et al., 2013a) . Thus, NA may potentially serve a more central role in conceptual models of smoking processes and behavior. Despite the relatively strong evidence for the role of PA and NA in smoking treatment outcomes, no work has evaluated how these factors may differentially predict early smoking milestones, including pretreatment dropout, smoking treatment nonresponse, and smoking treatment response.
Beyond smoking outcomes, PA and NA also may be critical to AS treatment initiation and responsiveness. For example, higher PA is theorized to promote creative problemsolving and improve cognitive flexibility (Chiew and Braver, 2011) . These adaptive qualities may be associated with better early treatment outcomes, particularly when participating in a novel treatment. Drawing from the broaden-and-build theory (Fredrickson, 1998; Fredrickson, 2004) , treatment-seeking individuals with elevated PA may respond to integrated treatment because these cigarette users may be more apt to deeply encode and utilize the novel strategies introduced during treatment. Thus, higher pretreatment PA may be an indicator of more positive early treatment outcomes, including treatment response. In contrast to higher PA, higher pretreatment NA may serve as a risk factor for poorer early treatment outcomes, including pretreatment dropout and treatment nonresponse. Indeed, robust evidence suggests elevated NA has the potential to negatively impact treatment (Hengartner, 2015) . Theoretically, individuals who smoke with greater pretreatment NA may be less likely to initiate or respond to AS treatment because of their tendency to orient toward behaviors that produce immediate reductions in NA symptoms (Shiffman et al., 2007; Langdon et al., 2016) . Thus, those with increased NA may be less likely to adhere to treatment protocol (O'Donohue and Levensky, 2006) , and therefore, evince poorer early AS outcomes.
Despite the empirical and theoretical support for PA and NA as clinically important factors for smoking cessation, no work has evaluated the predictive validity of these constructs across early treatment milestones within an integrated smoking treatment protocol. Elucidating factors that support or impede early treatment milestones has the potential to help clinicians identify individuals at the greatest risk for treatment dropout and nonresponse and inform treatment development of specialized, integrated interventions that aim to address the unique needs of individuals with the greatest difficulty quitting. Moreover, evaluating these factors as predictors of smoking and AS treatment responsiveness independently may be particularly important considering the effect of reducing AS during integrated care on smoking outcomes (Zvolensky et al., 2006; Zvolensky et al., 2018) . Indeed, the timeliness of this work is captured in the growing recognition for specialized smoking-cessation treatment to address the unique characteristics of current individuals who smoke (Kalman, 1998; Burns et al., 2016) . Thus, to accurately inform targeted treatment development and have a formidable impact on future generations of this work, it is necessary to evaluate early treatment milestones in the context of integrated smoking cessation treatment.
Together, the current study evaluated the independent effect of PA and NA on pretreatment dropout, treatment nonresponse, and treatment response within the context of an integrated smoking-AS treatment protocol (Schmidt et al., 2015) . Pretreatment drop out was defined as dropping out of the study before randomization (Vendetti et al., 2002) . Treatment response outcomes were operationalized in terms of smoking (ie, fail to maintain initial abstinence after completing treatment; Burns et al., 2016) and AS (ie, at least a 25% reduction in symptom severity; Garey et al., 2017) . Smoking and AS outcomes were evaluated independently. Thus, 4 unique models were examined. Across the 3 groups that comprised smoking treatment milestones (treatment dropout, treatment nonresponse, and treatment response), it was hypothesized that pretreatment levels of PA would be highest among smoking treatment responders, followed by nonresponders, and then, dropouts. It was further hypothesized that decreased PA would place a cigarette user at greatest odds for the poorest early treatment outcome, that is, pretreatment dropout. Additionally, it was hypothesized that pretreatment levels of NA would be lowest among smoking treatment responders, followed by nonresponders, and then, dropouts. It was further hypothesized that increased NA would place individuals who smoke at greatest odds for the poorest early treatment outcome, that is, pretreatment dropout. A similar pattern of association was hypothesized to emerge for the AS early treatment milestones.
METHOD Participants
Participants were 288 (50% female; M age ¼ 38.66, SD ¼ 13.67) treatment-seeking individuals who smoke (ie, interested in obtaining cessation treatment and motivated to quit). All participants were recruited from 2 sites (University of Vermont and Florida State University; clinicaltrials.gov #NCT01753141). To be eligible for inclusion participants had to be 18 years of age or older, daily cigarette users (eg, average !8 cigarettes per day for at least 1 year), and report a motivation to quit smoking (eg, at least 5 on a 10-point scale). Exclusion criteria included current use of any psychotherapy or pharmacotherapy for smoking cessation not provided by the researchers, current use of other tobacco products, and
Procedures
Data were collected during a large, multisite randomized controlled clinical trial examining the efficacy of 2 smoking-cessation interventions (Schmidt et al., 2015) . Briefly, eligible participants were randomized to one of two 4-session smoking-cessation treatments: Integrated Smoking Cessation Program; or Standard Care for Smoking Cessation Program. The Integrated Smoking Cessation (active) Program integrated interoceptive exposure, cognitive restructuring, and psychoeducation exercises developed for panic prevention; and standard of care treatment for standard smoking cessation. The Standard Care for Smoking Cessation Program (control) included the smoking-related component of the Integrated Care Smoking Cessation Program, and also a review of general health information not specific to anxiety or smoking (to maintain equal contact time across the 2 conditions). It is important to note that although anxiety symptoms were not directly targeted in the Standard Care intervention, it had a stress management component, and across both conditions, a significant average decrease in anxiety related symptoms was observed during the treatment period (Schmidt et al., 2015) . In addition to counseling, both treatment groups received nicotine replacement therapy via the transdermal nicotine patch, which was initiated at treatment session 4 (quit day). Treatment consisted of four 60-minute weekly sessions conducted by trained doctoral-level graduate students. All treatment was supervised by principal investigators (MJZ and NBS) and checked for treatment fidelity by independent reviewers. Data collection began in 2007 and concluded in 2014. The current study is based on secondary analyses of baseline (pretreatment), quit day, and 1-week follow-up data for participants who met eligibility criteria (see Fig. 1 for overview of the study design). Considering the present investigation focused on pretreatment dropout, and treatment nonresponse and response across 2 outcomes, only those who dropped out before initiating treatment and those who provided quit day or 1-week follow-up data were included in the present analyses. The study protocol was approved by the Institutional Review Boards at the University of Vermont and Florida State University.
Measures

Demographics Questionnaire
Demographic information included participant sex, age, and race/ethnicity.
Diagnostic Interview
The Structured Clinical Interview for DSM-IV Diagnosis of Axis I Disorders Non-Patient Version (SCID-NP) was used to describe the presence of current psychological disorders among the sample (First et al., 2007) . The DSM-IV assesses for mood disorder, anxiety disorders, obsessivecompulsive disorders, substance use disorders, and alcohol use disorders; participants meeting criteria for at least 1 disorder were grouped and compared with those not meeting criteria for any disorder. All interviews were audiotaped and reliability of 12.5% of interviews were checked for accuracy; no cases of disagreement were noted.
Fagerström Test for Cigarette Dependence
The Fagerström Test for Cigarette Dependence (FTCD) is a 6-item scale that assesses gradations in tobacco dependence (Heatherton et al., 1991; Fagerström, 2012) . The FTCD has adequate internal consistency and high test-retest reliability (Heatherton et al., 1991; Pomerleau et al., 1994) . The FTCD total score was used and internal consistency was low (a ¼ 0.63), which is not uncommon for this measure (Korte et al., 2013) .
Positive and Negative Affect Schedule
The Positive and Negative Affect Schedule (PANAS; Watson et al., 1988 ) is a self-report measure used to assess the degree to which respondents currently experience 20 different emotions and feelings (eg, excited, distressed). The measure yields 2 factors, positive affect (PANAS-PA) and negative affect (PANAS-NA), which have demonstrated strong psychometric properties (Watson et al., 1988) . In the present study, both subscales were included as predictors (PANAS-PA a ¼ 0.90; PANAS-NA a ¼ 0.90). 
Smoking Treatment Response
Self-reported smoking status was assessed in-person at the 1-week follow-up. The Timeline Follow-Back (TLFB; Sobell and Sobell, 1992; Brown et al., 1998) procedure was used to assess cigarette consumption at each day since the previous assessment. The assessment has demonstrated good reliability and validity with biochemical indices of smoking (Sobell and Sobell, 1996) . Self-reported abstinence was verified by expired carbon monoxide (CO) using a CMD/CO Series Carbon Monoxide Monitor (Model 3110; Spirometrics, Inc., Auburn, ME). Self-reported abstinence was over-ridden by a positive expired CO reading (>8 ppm). Smoking treatment response was defined as self-reported no smoking, not even a puff, in the 7 days before the 1-week follow-up assessment and biochemical verification of abstinence.
Anxiety Sensitivity Treatment Response
The Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007 ) is a 18-item measure, based in part upon the original Anxiety Sensitivity Index (Reiss et al., 1986) , in which participants are asked to respond to the extent they feel concerned about the possible aversive effects of their anxiety related symptoms. The responses are rated on a 5-point Likert scale from 0 (very little) to 4 (very much). For the current study, the total score (ASI-3 total) was used to assess AS treatment response (defined as at least a 25% reduction in symptom severity from baseline to quit day; Garey et al., 2017) . The ASI-3 has sound psychometric properties among smoking populations (Farris et al., 2015) . The ASI-3 demonstrated strong internal consistency in the present study (baseline: a ¼ 0.93; quit day: a ¼ 0.91).
Analytic Strategy
Data analyses were completed using SPSS version 24. First, descriptive and bivariate relations were examined among study variables. Second, multinomial logistic regression models were calculated to independently evaluate the predictive validity of pretreatment PA and pretreatment NA on outcome status. Early treatment milestones were defined across 3 groups: pretreatment dropouts; treatment nonresponders (ie, participants who complete treatment, but do not demonstrate an improvement in outcomes); and treatment responders (ie, those who compete treatment and demonstrated an improvement in outcomes). Outcomes were defined in terms of smoking abstinence during the first week after quit and AS reduction from baseline to quit day. Thus, 4 models were conducted: pretreatment PA as a unique predictor of smoking treatment milestones; pretreatment NA as a unique predictor of smoking treatment milestones; pretreatment PA as a unique predictor of AS treatment milestones; and pretreatment NA as a unique predictor of AS treatment milestones; pretreatment dropouts served as the reference group in analyses. Post hoc tests were conducted to evaluate mean comparisons across groups; tests were subjected to a Bonferroni adjusted alpha for multiple comparisons. Based on prior research (Garey et al., 2017) , covariates included sex, presence of psychopathology, FTCD, and treatment condition. All models evinced a nonsignificant chi-square goodness of fit statistic, suggesting adequate model fit.
RESULTS
Descriptive and Bivariate Correlations
Fifty-six participants dropped out before initiating the study. In all, 177 participants provided CO and timeline follow-back information at the 1-week follow-up (nonresponders to smoking treatment: n ¼ 88; responder to smoking treatment: n ¼ 89), and 213 provided quit day data on AS (nonresponders to AS treatment: n ¼ 106; responder to smoking treatment: n ¼ 107).
Most of the sample identified as White (87.7%). On average, participants reported smoking 18 cigarettes per day (SD ¼ 8.48) and had been a daily smoker for 20.3 years (SD ¼ 13.51). A moderate level of cigarette dependence was observed based on the FTCD (M ¼ 5.35, SD ¼ 2.13; Heatherton et al., 1991) . Table 1 presents descriptive statistics and bivariate correlations for study variables.
Multinomial Logistic Regressions
PA Predictor of Smoking Treatment Milestones
Pretreatment PA did not significantly distinguish the 3 groups (see Table 2 ). Presence of psychopathology emerged as a marginally significant predictor (x 2 [2] ¼ 5.43, P ¼ 0.07).
NA Predictor of Smoking Treatment Milestones
Pretreatment NA significantly predicted smoking outcome status (see Table 2 ). Evaluation of parameter estimates suggested an increase in baseline NA was associated with an increased likelihood of being a pretreatment dropout relative Marginal means were highest among participants who dropped out before treatment, followed by treatment nonresponders and treatment responders (M ¼ 20.17, 18.17, 17.71, respectively) .
PA Predictor of AS Treatment Milestones
Pretreatment PA did not significantly distinguish the 3 groups (see Table 3 ). Sex emerged as a significant predictor of AS outcome status (x 2 [2] ¼ 6.66, P ¼ 0.04); the parameter estimates suggested that men are marginally less likely than women to be a treatment responder than to be a pretreatment dropout (OR 0.59, 95% CI 0.34-1.03).
NA Predictor of AS Treatment Milestones
Pretreatment NA significantly predicted AS outcome status (see Table 3 ). Evaluation of parameter estimates suggested an increase in pretreatment NA was associated with an increased likelihood of being a pretreatment dropout relative to a treatment responder (OR 0.92, 95% CI 0.88-0.98). Post hoc tests revealed a significant mean difference between pretreatment dropouts and responders to smoking treatment (P ¼ 0.05); no other pair-wise comparisons significantly differed (Ps > 0.05). Marginal means were highest among participants who dropped out before treatment, followed by treatment nonresponders and treatment responders (M ¼ 20.45, 18.93, 17.57, respectively) . Across smoking and AS outcomes, similar results were obtained when PA and NA were entered as concurrent covariates (the results can be obtained from the authors upon request).
DISCUSSION
The current study examined pretreatment PA and NA as unique predictors of pretreatment dropout, treatment nonresponse, and treatment response within the context of an integrated smoking-AS treatment protocol. Smoking outcomes and AS outcomes were evaluated independently. In partial support of hypotheses, pretreatment NA emerged as a significant predictor of early outcome status across both smoking and AS outcomes. Specifically, after controlling for sex, presence of psychopathology, tobacco dependence, and treatment, increased pretreatment NA was associated with an increased likelihood of early dropout versus responding to treatment across both outcomes, and marginally associated with an increased likelihood of early dropout versus not responding to the smoking treatment. Pretreatment PA did not significantly differentiate the targeted groups.
Although past work has implicated PA and NA as predictors of treatment outcomes (Carmody et al., 2007; Bränström et al., 2010a; Leventhal et al., 2013b) , this is the first empirical study to evaluate pretreatment PA and NA as unique predictors of poor early treatment milestones across a variety of outcomes (ie, pretreatment dropout and treatment nonresponse status). Consistent with extant work on smoking outcomes (Leventhal et al., 2013a) , the present evidence suggests that pretreatment NA may play a central role in identifying those at greatest risk for dropping out versus those most likely to respond to treatment. Importantly, the present study extends prior research by suggesting that in addition to pretreatment NA serving a unique predictor early treatment outcomes for smoking, pretreatment NA also is clinically important to early treatment outcomes for AS. Considering the growth in the development of integrated treatments to assist individuals who smoke and are at increased risk for relapse and quit difficulty (Kalman, 1998; Burns et al., 2016) , this timely investigation provides novel support of pretreatment NA as a potential risk marker for poorer early treatment outcomes across both substance use and mental health factors. It is important to note that pretreatment NA significantly differentiated those at increased risk for pretreatment dropout and those most likely to respond to treatment. Thus, pretreatment NA did not significantly differ between pretreatment dropouts and nonresponders, or nonresponders and responders. Although these findings were inconsistent with hypotheses, they provide further insight into the nuanced correlates of group classifications for early treatment outcomes. Indeed, whereas extant research suggests unique antecedents exists that identify those at greatest risk for dropping out of psychosocial interventions, and also those likely and unlikely to respond to treatment (O'Donohue and Levensky, 2006; Hengartner, 2015) , before the current investigation, no work had evaluated pretreatment dropout to treatment responsiveness status in a comprehensive, independent study. Thus, the current study provides a relatively more holistic investigation for antecedents uniquely related to several different early treatment milestones, and highlights pretreatment NA as a putative risk factor that distinguishes those at greatest risk for pretreatment dropout and those most likely to respond to treatment.
Despite the nonsignificant findings across the associations for pretreatment dropouts and nonresponders, and nonresponders and responders, as hypothesized, a tiered mean level of pretreatment NA was observed, such that the highest values were observed among pretreatment dropouts, followed by nonresponders, and then, treatment responders with the lowest mean levels of pretreatment NA. Although such findings provide only basic descriptive evidence for differences in pretreatment NA across early treatment milestones, it supports the continued investigation for the role of pretreatment NA in early treatment dropout and response status. Moreover, it will be of clinical importance for future work to investigate additional factors that may discriminate pretreatment dropouts, treatment nonresponders, and treatment responders.
Contrary to hypotheses, pretreatment PA did not significantly differ across groups within the context of smoking or AS. According to theoretical work (Fredrickson et al., 2008; Fredrickson, 2013) , one would expect for individuals who smoke and report higher pretreatment PA to utilize the treatment elements and thereby be more likely to respond to treatment. Yet, the present data show that pretreatment PA is not an indicator of early treatment milestones. The lack of a statistically significant pretreatment difference in PA across groups may have emerged, in part, because of the unique characteristics of the sample. More than 40% of the present sample met criteria for a current psychiatric illness. Thus, their pretreatment PA may not be as pertinent as their pretreatment NA. Future investigations may consider the impact of change in PA during the course of treatment on early treatment milestones, as change in PA may be an under recognized but important clinical construct (Taylor et al., 2017) . Clinically, the present data implicate NA as a putative risk factor for pretreatment dropout. Thus, it may be advisable to clinicians to assess NA at intake. Such assessment would permit early intervention to enhance treatment motivation and increase the likelihood of treatment initiation (Hengartner, 2015) . Moreover, based on the present data, and also theoretically driven work indicating NA relief as a primary motivator for substance use (Baker et al., 2004) , it may be advisable for integrated smoking cessation treatment to specifically target and monitor NA during the course of treatment. Specifically, providing psychoeducation on the relation between NA states and smoking, and also methods to help manage NA, including mindfulness techniques (Gonzalez et al., 2009) , may lead to improved treatment responsiveness. Additionally, assessing NA before and during treatment may have the potential to inform individualized treatment planning, and also necessary treatment modifications to increase treatment efficacy.
The study limitations warrant comment. First, the sample consisted of primarily White, community-recruited, treatment-seeking daily cigarette users with moderate levels of cigarette dependence. It will be useful for future studies to replicate the study among a more diverse sample, in terms of ethnicity and smoking behavior. Second, the study examined treatment response at 1-week post-treatment. Future work would benefit from examining these relations across a larger post-treatment period to determine long-term treatment responders. Third, the internal consistency of the FTCD items was relatively low, leaving speculation as to the validity of this measure to assess cigarette dependence. It is worth noting that Cronbach alpha values are fairly sensitive to the number of items in each scale and it is not uncommon to find lower Cronbach values with shorter scales (eg, scales with fewer than 10 items; DeVellis, 2017). Nevertheless, additional work is needed to examine if the tested relations hold while controlling for cigarette dependence that is assessed by a more internally consistent measure. Finally, although the PANAS capture an array of positive and negative emotions, the degree of emotional arousal association within the context of such emotions is limited. In particular, the measure tends to focus on high arousal emotions (ie, excited, hostile, enthusiastic). Thus, the present finding may be limited to positive and negative affect that is captured by relatively high arousal states. Future work may consider evaluating the positive and negative affective states that consider moderate or low arousal emotional states (ie, calm, peaceful, isolated).
CONCLUSIONS
Overall, the present study serves as an initial investigation on the role of PA and NA across early treatment outcomes for smoking and AS among a sample of treatment-seeking persons who smoke. The results suggest that greater pretreatment NA may be a characteristic to identify those at greatest risk for dropping out of treatment versus responding to treatment. This information serves to inform best practices to triaged smoking care and individualized treatment efforts. The current findings address an important gap in the literature in identifying predictors of early treatment outcomes that may have significant clinical utility in the treatment of affectively vulnerable individuals who smoke. Future work may consider evaluating the impact of pretreatment NA on time to smoking and mood lapse/relapse within the context of integrated mood and smoking treatment.
